HER2+ 유방암

5개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved5 programs
AntibodyCurated CoreFDAAstellasApproved

zolbetuximab (Vyloy, IMAB362, zolbetuximab-clzb, claudiximab)

CLDN18.2-positive HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma · CLDN18.2 (claudin-18.2)

#CLDN182claudin-182#Antibody#Approved#FDA-approved#BioJungboMoa-pick+4
Trials 26Status Approved
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin(RC48) Plus Tratuzumab)

HER2-positive Gastric Cancer; HER2-positive Gastroesophageal Junction Adenocarcinoma · HER2

#HER2#ADC#Phase2#Popular#antibody-drug-conjugate+4
Trials 91Status Recruiting
AntibodyLimited DatastaleAkesoPhase 2

cadonilimab (cadonilimab)

Metastatic HER2 Positive Gastroesophageal Junction Cancer · Salivary Gland Carcinoma

#SalivaryGlandCarcinoma#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 85Status Recruiting
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab vedotin + Sintilimab + Multimodality radiotherapy)

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#HER2-positiveAdvancedGastricCanc+1
Trials 1Status Recruiting
AntibodyLimited DatastaleTriumvira Immunologics, Inc.Phase 2

pembrolizumab (Keytruda, TAC01-HER2 plus pembrolizumab)

HER2 Positive Gastric Cancer; Metastatic HER2 Positive Gastroesophageal Junction Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#HER2PositiveGastricCancer+2
Trials 1Status Discontinued